AtaiBeckley Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from __________ to __________Commission File Number: 001-43037 AtaiBeckley Inc.(Exact name of registrant as specified in its charter) 41-3357923(I.R.S. EmployerIdentification No.) (332) 282-0507(Registrant’s telephone number, including area code)N/A(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of August7, 2026, the registrant had 370,864,669 shares of common stock, par value $0.01 per share, outstanding. ATAIBECKLEY INC. FORM 10-Q Table of Contents Forward-Looking Statements PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited) 3Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 20253Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2026 and 20254Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2026 and20255Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June30, 2026 and 20256Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 20257Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations40Item 3.Quantitative and Qualitative Disclosures About Market Risk54Item 4.Controls and Procedures55PART II.OTHER INFORMATION56 Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures 5656585858585960 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-lookingstatements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the SecuritiesAct of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Allstatements contained in this Quarterly Report other than statements of historical fact are forward-looking statements, includingwithout limitation statements regarding our pending Merger (as defined below) future operating results and financial position; thesuccess, cost, and timing of development of our product candidates, including the progress of preclinical studies and clinical trialsand related milestones; the commercialization of our current product candidates and any other product candidates we may identifyand pursue, if approved, including, in the event the Merger is not completed, our ability to successfully build a specialty sales forceand commercial infrastructure to market our current product candidates and any other product candidates we may identify andpursue; the timing of and our ability to obtain and maintain regulatory approvals; our business strategy and plans; the ability togenerate revenue from any current or future licensing agreements and other strategic arrangements, the sufficiency of our cash andcash equivalents and short-term securities to fund our operations; the val